Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts
13.2.2025 13:00:00 CET | Business Wire | Press release
Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership.
- Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India.
-
Flowchem has bolstered its technology team with several key technical hires, significantly enhancing its product development capabilities. Dr. Lu-Chien Chou is a recognized leader in the field who has led cutting-edge DRA research at Baker Hughes (NASDAQ:BKR) and other DRA providers. John Stephens joins Flowchem after decades of experience in industrial chemical research and development and manufacturing, including at Siege Engineering and PPG Industries (NYSE:PPG). These scientific leaders ensure that Flowchem remains at the forefront of DRA technology while maintaining its industry-leading quality and performance in reducing costs and emissions for customers across multiple product lines.
-
The Company has assembled a best-in-class Board of Directors of senior industry leaders with energy and chemicals experience:
- Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International
- Joe Blount – former President and CEO, Colonial Pipeline; former CEO, Century Midstream LLC; former Chair of the Association of Oil Pipe Lines (AOPL)
- Scott Rogan – CFO, Eagle LNG Partners; former SVP, Targa Resources; former Partner and head of midstream investing, Energy Capital Partners
- Chris Oversby – former CEO, Optum Energy Solutions, a DRA technology business; former chemicals executive at Baker Hughes, Clariant & Univar
- Sean Rice – Managing Partner, SCF Partners
- Dan West – Managing Director, SCF Partners
- Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International
Flowchem's CEO, Jon Blair, commented, “I am pleased to announce the appointment of Shivali Agarwal to COO. Shivali is a tremendous leader with a proven track record of success, and her operational expertise will enhance our efforts going forward. Our strengthened technology team and strategic board of directors will also be instrumental in improving our DRA solutions and enhancing the value we provide to our customers worldwide.”
Dan West, Managing Director at SCF Partners, stated, “Our team at Flowchem has demonstrated significant success in creating value for both customers and shareholders by making infrastructure operations safer, more efficient, and less emissions-intensive. We are excited to add these key leaders to reinforce and accelerate the company’s growth.”
About Flowchem, Val-Tex, and Sealweld
Flowchem is a leading supplier of Drag Reducing Agents (“DRA”) which optimize pipeline flow and increase throughput capacity. Use of Flowchem DRA enables infrastructure operators across the globe to reduce energy consumed in pumping operations, which in turn reduces both costs and associated greenhouse gas emissions and maximizes overall profitability of infrastructure operations. Flowchem provides flow consultation and turnkey solutions for pipeline applications worldwide. For more information, please visit www.flowchem-dra.com.
Val-Tex, founded in 1962, is one of the industry’s premier providers of high-quality valve maintenance products such as sealants, lubricants, fittings, and injection equipment. Val-Tex’s longstanding commitment to product excellence and customer satisfaction has earned the trust and recommendation of the world’s leading valve manufacturers. To learn more, please visit www.valtex.com.
Sealweld has provided superior valve care products and services since 1969, with a focus on the safe reduction and elimination of pipeline valve leakage. Decades of experience and development of practical solutions have resulted in high-performing valve care products equally suited to either gas or liquid pipelines. For more information, visit www.sealweld.com.
About SCF Partners
Founded in 1989, SCF provides equity capital and strategic growth assistance to build and grow leading energy service, equipment, and technology companies that operate throughout the world. SCF has invested in more than 80 platform companies and made more than 400 additional acquisitions to develop 18 publicly listed energy service and equipment companies over its history. The firm is headquartered in Houston, Texas, and has offices in Calgary, Aberdeen, and Australia. For more information, please visit www.scfpartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210052408/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom